Target Validation Information
Target ID T05409
Target Name Neutral endopeptidase
Target Type
Successful
Drug Potency against Target CGS-26303 Drug Info IC50 = 0.9 nM
Ilepatril Drug Info Ki = 5 nM [552392]
CGS-314447 Drug Info IC50 = 6.9 nM
9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid Drug Info IC50 = 4 nM [533959]
Omapatrilat Drug Info IC50 = 5 nM [527799]
SQ-26332 Drug Info IC50 = 400 nM [527799]
SCH-54470 Drug Info IC50 = 90 nM [530505]
References
Ref 552392Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res. 2003 Nov 1;60(2):447-54.
Ref 533959J Med Chem. 1993 Nov 26;36(24):3821-8.Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.
Ref 527799J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm.
Ref 527799J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm.
Ref 530505J Med Chem. 2010 Jan 14;53(1):208-20.Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.